The bipartisan obsession with "capping" insulin costs is a masterclass in political theater. It is the legislative equivalent of putting a designer Band-Aid on a severed limb and asking the patient to admire the pattern.
Every time a new bill crawls through Congress promising to lower out-of-pocket costs to $35, the media treats it like a medical miracle. Advocates celebrate. Politicians take victory laps. Meanwhile, the actual mechanics of the American healthcare machine remain untouched, grinding away at the very people these bills claim to protect. You might also find this related coverage useful: The $2 Million Mirage Why Your Breakthrough Drug is a Financial Time Bomb.
If you think a price cap is the "solution" to the insulin crisis, you aren’t paying attention to how the money actually moves.
The Rebate Trap That Everyone Ignores
The standard narrative is simple: Big Pharma is greedy, so they raise prices. While pharma companies are hardly saints, the "greedy manufacturer" trope is a convenient distraction from the real architects of high costs: Pharmacy Benefit Managers (PBMs). As extensively documented in latest coverage by Medical News Today, the effects are widespread.
PBMs—middlemen like CVS Caremark, Express Scripts, and OptumRx—control which drugs get covered by insurance. They don't get paid for saving you money; they get paid via rebates based on a percentage of the drug's list price.
Imagine a scenario where a manufacturer wants to lower the price of their insulin to $50. The PBM will often block that cheaper drug from the formulary because a $50 drug offers a tiny rebate compared to a $500 drug. If the manufacturer drops the list price, the PBM loses profit. If the PBM loses profit, they kick the drug off the insurance plan.
By focusing solely on what the patient pays at the counter, bipartisan bills ignore the "gross-to-net" bubble. We are subsidizing a system where the list price stays astronomical to satisfy the middlemen, while the government uses taxpayer money or forced private insurance shifts to cover the difference. It isn't a price cut; it’s a shell game.
The $35 Cap is a Subsidy for Insurance Companies
When a bill mandates a $35 cap, the cost of the insulin doesn't actually drop to $35. The remaining $300 or $600 still gets paid to the pharmacy. Who pays it? The insurance provider. And where does the insurance provider get that money? From your monthly premiums and your employer's bottom line.
We are cheering for a policy that effectively tells insurance companies, "Don't worry, you can keep paying inflated prices to PBMs and manufacturers, just hide the cost in the premium increase next year so the voter doesn't see it at the pharmacy window."
It is a short-sighted strategy that treats the symptom while the underlying infection—monopolistic vertical integration—spreads. Unless we address why the insulin costs $600 to begin with, a $35 cap is just a way to make the theft feel less painful in the moment.
The Biosimilar Myth
Advocates often point to the rise of biosimilars (generic versions of complex drugs) as the ultimate savior. They argue that once we have more "generic" insulin, competition will naturally drive prices down.
This ignores the "Evergreening" tactic used by companies like Eli Lilly, Novo Nordisk, and Sanofi. They don't just sit back and let patents expire. They tweak the delivery device—the pen, the needle, the concentration—and file new patents. They create a "patent thicket" that ties up competitors in court for a decade.
Even when a biosimilar makes it to market, the PBMs (remember them?) often refuse to prefer it because the brand-name manufacturer offers a "rebate wall." They tell the PBM, "If you put that cheap biosimilar on your list, we will pull the rebates for all our other blockbuster drugs."
The market isn't broken; it's rigged. No amount of "bipartisan hope" changes the fact that the players in this game have a fiduciary responsibility to keep prices high.
Why We Are Asking the Wrong Questions
The "People Also Ask" section of any search engine regarding insulin is a graveyard of misunderstanding.
- "Why is insulin so expensive?" (Because the PBM business model demands high list prices).
- "Will the new bill make insulin affordable?" (Only for the person at the window, not for the economy or the taxpayer).
We should be asking why the U.S. government allows three companies to control 90% of the global insulin market while simultaneously allowing three PBMs to control 80% of the U.S. prescription market.
Real disruption doesn't come from a price cap. It comes from:
- Total Rebate Transparency: Forcing PBMs to pass 100% of rebates directly to the consumer at the point of sale, effectively destroying their incentive to prefer high-priced drugs.
- Public Manufacturing: If the "market" cannot provide a 100-year-old hormone at a reasonable price, the government should stop begging and start building. California's attempt to manufacture its own insulin is a far more "contrarian" and effective threat to the status quo than any federal bill currently on the floor.
- Banning Vertical Integration: An insurance company should not own a PBM, which in turn owns the pharmacy that fills your script. That is a closed loop designed to extract maximum capital from the sick.
The Harsh Reality of "Advocacy"
Many diabetes advocacy groups receive significant funding from the very pharmaceutical companies they are supposed to be "fighting." This leads to a watered-down version of advocacy that focuses on "access" and "affordability" (which usually means "make insurance pay for it") rather than "price" (which means "make the drug cheaper").
When you hear a spokesperson "crossing their fingers" for a bill, ask yourself if they are hoping for a change in the system or just a change in the optics.
Insulin is a commodity. It is not a luxury good. It is not a new technology. It is a century-old discovery that the inventors sold for $1 because they believed it belonged to the world. The fact that we are still debating "caps" in 2026 is an indictment of our entire regulatory framework.
Stop celebrating the $35 cap. It’s a bribe to keep you from demanding a system that actually works.
If you want to fix the insulin crisis, you don't cap the price; you break the cartel.
